The present disclosure relates to materials and methods for evaluating prostate cancer using binding entities (such as antibodies) that bind to the N-terminus and the C-Terminus of androgen receptor. Prostate samples are histochemically labeled for the N-terminus and the C-Terminus of androgen receptor, and a ratio between the binding of the N- and C-terminal antibodies is determined.

Improved methods and systems for diagnosing and for treating Cushing's syndrome and Cushing's Disease are provided herein, including methods and systems for concurrently treating Cushing's syndrome and differentially diagnosing Cushing's Disease from Ectopic Cushing's Syndrome in a patient with an established diagnosis of ACTH-dependent Cushing's syndrome. Treatment methods can use glucocorticoid receptor antagonists (GRAs), which differentially affect the ratio of cortisol to ACTH levels in patients having Cushing's Disease versus patients having Ectopic Cushing's Syndrome. Methods for concurrently treating and differentially diagnosing Cushing's Disease from Ectopic Cushing's Syndrome include obtaining baseline cortisol and ACTH levels of a patient, treating the patient with a GRA according to a protocol that would typically substantially elevate cortisol levels, obtaining post-treatment cortisol and ACTH levels of the patient, determining a differential relationship between baseline cortisol and ACTH levels and post-treatment cortisol and ACTH levels and providing a positive diagnosis based on the differential relationship.

The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer.

The present technology generally relates to methods and compositions relevant to the prediction that a subject with and/or after treatment for DCIS will experience a subsequent ipsilateral breast event that is a DCIS recurrence, an invasive breast cancer, both a DCIS recurrence and invasive cancer, or neither. The technology can assist one with how to treat such subjects.

The present disclosure generally relates to cancer and methods of treating and diagnosing cancer.

The present invention relates to a genetically mutated bacteria strain for detecting an estrogenic compound and a method for detecting an estrogenic compound by using the same. More specifically, the present invention relates to a bacteria strain having an ability to detect an estrogenic compound, transformed by plasmid A comprising base sequences in which a gene for encoding a coactivator interacting with an estrogen receptor ligand binding domain (ER LBD) is conjugated to a gene for encoding λCI protein, and plasmid B in which a gene for encoding an estrogen receptor ligand binding domain (ER LBD) is conjugated to a gene for encoding αNTD protein, and a method for detecting an estrogenic compound by using same. The present invention can provide genetically mutated bacteria for detecting an estrogenic compound and a method for detecting an estrogenic compound by using same since the bacteria are based on estrogen receptor protein originated from the human body, and thus are environmentally friendly, and the detection of the bacteria can be performed in a very short time with low cost and labor by virtue of a relatively simple process.

The present invention describes a method for detecting NEPC in a patient afflicted with prostate cancer comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to detect circulating tumor cells (CTC), and (b) determining presence or absence of a CTC subpopulation associated with NEPC comprising detecting a measurable feature of each biomarker in a panel of morphological and protein biomarkers, wherein the presence of the CTC subpopulation associated with NEPC is indicative of NEPC. In other embodiments, the biomarkers for the CTC subpopulation associated with NEPC comprise small size, absence of Androgen Receptor (AR.sup.−), and presence of nucleoli (nucleoli.sup.+). In additional embodiments, the methods of the invention further comprise molecular analysis of the CTCs.

The present technology generally relates to methods and compositions relevant to the prediction that a subject with and/or after treatment for DCIS will experience a subsequent ipsilateral breast event that is a DCIS recurrence, an invasive breast cancer, both a DCIS recurrence and invasive cancer, or neither. The technology can assist one with how to treat such subjects.

Methods and compositions for treating cancer, particularly breast cancer, are disclosed.

Certain aspects of this disclosure relate to a method that comprises contacting a mammalian cell with a glucocorticoid receptor ligand and a myostatin receptor ligand, thereby activating the glucocorticoid receptor and said myostatin receptor. A screening assay employing the same is also provided.